Top

Published in:

01-11-2017 | Original Article

Electronic versus paper-pencil methods for assessing chemotherapy-induced peripheral neuropathy

Authors: Robert Knoerl, Evan Gray, Carrie Stricker, Sandra A. Mitchell, Kelsey Kippe, Gloria Smith, William N. Dudley, Ellen M. Lavoie Smith

Published in: Supportive Care in Cancer | Issue 11/2017

Abstract

Purpose

The aim of this study is to examine and compare with the validated, paper/pencil European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Chemotherapy-Induced Peripheral Neuropathy Scale (QLQ-CIPN20), the psychometric properties of three electronically administered patient reported outcome (PRO) measures of chemotherapy-induced peripheral neuropathy (CIPN): (1) the two neuropathy items from the National Cancer Institute’s Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE), (2) the QLQ-CIPN20, and (3) the 0–10 Neuropathy Screening Question (NSQ).

Methods

We employed a descriptive, cross-sectional design and recruited 25 women with breast cancer who were receiving neurotoxic chemotherapy at an academic hospital. Participants completed the paper/pencil QLQ-CIPN20 and electronic versions of the QLQ-CIPN20, PRO-CTCAE, and NSQ. Internal consistency reliability, intraclass correlation, and concurrent and discriminant validity analyses were conducted.

Results

The alpha coefficients for the electronic QLQ-CIPN20 sensory and motor subscales were 0.76 and 0.75. Comparison of the electronic and paper/pencil QLQ-CIPN20 subscales supported mode equivalence (intraclass correlation range >0.91). Participants who reported the presence of numbness/tingling via the single-item NSQ reported higher mean QLQ-CIPN20 sensory subscale scores (p < 0.001). PRO-CTCAE neuropathy severity and interference items correlated well with the QLQ-CIPN20 electronic and paper/pencil sensory (r = 0.76; r = 0.70) and motor (r = 0.55; r = 0.62) subscales, and with the NSQ (r = 0.72; r = 0.44).

Conclusion

These data support the validity of the electronically administered PRO-CTCAE neuropathy items, NSQ, and QLQ-CIPN20 for neuropathy screening in clinical practice. The electronic and paper/pencil versions of the QLQ-CIPN can be used interchangeably based on evidence of mode equivalence.

Argyriou AA, Bruna J, Marmiroli P, Cavaletti G (2012) Chemotherapy-induced peripheral neurotoxicity (CIPN): an update. Crit Rev Oncol Hematol 82(1):51–77. doi:10.1016/j.critrevonc.2011.04.012 CrossRefPubMed

Cavaletti G, Cornblath DR, Merkies IS et al (2013) The chemotherapy-induced peripheral neuropathy outcome measures standardization study: from consensus to the first validity and reliability findings. Ann Oncol 24(2):454–462CrossRefPubMed

Hershman DL, Lacchetti C, Dworkin RH et al (2014) Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 32(18):1941–1967. doi:10.1200/JCO.2013.54.0914 CrossRefPubMed

Kautio AL, Haanpaa M, Kautiainen H, Kalso E, Saarto T (2011) Burden of chemotherapy-induced neuropathy—a cross-sectional study. Support Care Cancer 19(12):1991–1996. doi:10.1007/s00520-010-1043-2 CrossRefPubMed

Mols F, Beijers T, Vreugdenhil G, van de Poll-Franse L (2014) Chemotherapy-induced peripheral neuropathy and its association with quality of life: a systematic review. Support Care Cancer 22(8):2261–2269CrossRefPubMed

Seretny M, Currie GL, Sena ES et al (2014) Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis. Pain 155(12):2461–2470CrossRefPubMed

Saif MW, Reardon J (2005) Management of oxaliplatin-induced peripheral neuropathy. Ther Clin Risk Manag 1(4):249–258PubMedPubMedCentral

Smith EML, Bridges CM, Kanzawa G et al (2014) Cancer treatment-related neuropathic pain syndromes—epidemiology and treatment: an update. Curr Pain Headache Rep 18(11):459. doi:10.1007/s11916-014-0459-7 CrossRefPubMed

Speck RM, Sammel MD, Farrar JT et al (2013) Impact of chemotherapy-induced peripheral neuropathy on treatment delivery in nonmetastatic breast cancer. J Oncol Pract 9(5):e234–e240. doi:10.1200/JOP.2012.000863 CrossRefPubMed

10.

Stubblefield MD, Burstein HJ, Burton AW et al (2009) NCCN task force report: management of neuropathy in cancer. J Natl Compr Canc Netw 7(Suppl 5):S1-NaN-8

11.

Smith EM, Beck SL, Cohen J (2008) The total neuropathy score: a tool for measuring chemotherapy-induced peripheral neuropathy. Oncol Nurs Forum 35(1):96–102. doi:10.1188/08.ONF.96-102 CrossRefPubMed

12.

Smith EML, Bakitas MA, Homel P et al (2009) Using quality improvement methodology to improve neuropathic pain screening and assessment in patients with cancer. J Cancer Educ 24(2):135–140. doi:10.1080/08858190902854715 CrossRef

13.

Bakitas MA Background noise: the experience of chemotherapy-induced peripheral neuropathy. Nurs Res 56(5):323–331. doi:10.1097/01.NNR.0000289503.22414.79 CrossRefPubMed

14.

Binner M, Ross D, Browner I (2011) Chemotherapy-induced peripheral neuropathy: assessment of oncology nurses’ knowledge and practice. Oncol Nurs Forum 38(4):448–454CrossRefPubMed

15.

Smith EM (2013) Current methods for the assessment and management of taxane-related neuropathy. Clin J Oncol Nurs 17(Suppl):22–34CrossRefPubMed

16.

Griffith KA, Merkies IS, Hill EE, Cornblath DR (2010) Measures of chemotherapy-induced peripheral neuropathy: a systematic review of psychometric properties. J Peripher Nerv Syst 15(4):314–325. doi:10.1111/j.1529-8027.2010.00292.x CrossRefPubMed

17.

Cavaletti G, Frigeni B, Lanzani F et al (2010) Chemotherapy-induced peripheral neurotoxicity assessment: a critical revision of the currently available tools. Eur J Cancer 46(3):479–494. doi:10.1016/j.ejca.2009.12.008 CrossRefPubMed

18.

Postma TJ, Aaronson NK, Heimans JJ et al (2005) The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: the QLQ-CIPN20. Eur J Cancer 41(8):1135–1139CrossRefPubMed

19.

Smith EML, Barton DL, Qin R, Steen PD, Aaronson NK, Loprinzi CL (2013) Assessing patient-reported peripheral neuropathy: the reliability and validity of the European Organization for Research and Treatment of cancer QLQ-CIPN20 questionnaire. Qual Life Res 22(10):2787–2799CrossRefPubMedPubMedCentral

20.

National Cancer Institute (2010) Common Terminology Criteria for Adverse Events v 4.3 (CTCAE)

21.

Basch E, Jia X, Heller G et al (2009) Adverse symptom event reporting by patients vs clinicians: relationships with clinical outcomes. J Natl Cancer Inst 101(23):1624–1632. doi:10.1093/jnci/djp386 CrossRefPubMedPubMedCentral

22.

Postma TJ, Heimans JJ, Muller MJ, Ossenkoppele GJ, Vermorken JB, Aaronson NK (1998) Pitfalls in grading severity of chemotherapy-induced peripheral neuropathy. Ann Oncol 9(7):739–744CrossRefPubMed

23.

Alberti P, Rossi E, Cornblath DR et al (2014) Physician-assessed and patient-reported outcome measures in chemotherapy-induced sensory peripheral neurotoxicity: two sides of the same coin. Ann Oncol 25(1):257–264. doi:10.1093/annonc/mdt409 CrossRefPubMedPubMedCentral

24.

Atkinson TM, Ryan SJ, Bennett AV et al (2016) The association between clinician-based common terminology criteria for adverse events (CTCAE) and patient-reported outcomes (PRO): a systematic review. Support Care Cancer. doi:10.1007/s00520-016-3297-9 CrossRefPubMedPubMedCentral

25.

Atkinson TM, Li Y, Coffey CW et al (2012) Reliability of adverse symptom event reporting by clinicians. Qual Life Res 21(7):1159–1164. doi:10.1007/s11136-011-0031-4 CrossRefPubMed

26.

Kotronoulas G, Kearney N, Maguire R et al (2014) What is the value of the routine use of patient-reported outcome measures toward improvement of patient outcomes, processes of care, and health service outcomes in cancer care? A systematic review of controlled trials. J Clin Oncol 32(14):1480–1501. doi:10.1200/JCO.2013.53.5948 CrossRefPubMed

27.

Dueck AC, Mendoza TR, Mitchell SA et al (2015) Validity and reliability of the US National Cancer Institute’s Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). JAMA Oncol 1(8):1051–1059. doi:10.1001/jamaoncol.2015.2639 CrossRefPubMedPubMedCentral

28.

Basch E, Reeve BB, Mitchell SA, et al (2014) Development of the National Cancer Institute’s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). J Natl Cancer Inst 106(9). doi:10.1093/jnci/dju244 CrossRefPubMedPubMedCentral

29.

Hay JL, Atkinson TM, Reeve BB et al (2014) Cognitive interviewing of the US National Cancer Institute’s Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). Qual Life Res 23(1):257–269. doi:10.1007/s11136-013-0470-1 CrossRefPubMed

30.

Fayers P, Aaronson N, Bjordal K, et al (2001) EORTC QLQ-C30 Scoring Manual. 3rd ed. Brussels; file:///Users/rjknoerl1/Downloads/EORTC_QLQ_C30 _scoring_Manual (1).pdf

31.

Knoerl R, Dudley WN, Smith G, Bridges C, Kanzawa-Lee G, Lavoie Smith EM (2016) Pilot testing a web-based system for the assessment and management of chemotherapy-induced peripheral neuropathy. CIN Comput Informatics Nurs 1. doi:10.1097/CIN.0000000000000320 PubMed

32.

Eisinga R, Grotenhuis M, Pelzer B (2013) The reliability of a two-item scale: Pearson, Cronbach, or Spearman-Brown? Int J Public Health 58(4):637–642. doi:10.1007/s00038-012-0416-3 CrossRefPubMed

33.

Ferguson CJ An effect size primer: a guide for clinicians and researchers. doi:10.1037/a0015808 CrossRef

34.

Cohen J (1988) Statistical Power Analysis for the Behavioral Sciences, 2nd edn. Erlbaum Associates, Hillsdale

35.

Shrout PE, Fleiss JL (1979) Intraclass correlations: uses in assessing rater reliability. Psychol Bull 86(2):420–428CrossRefPubMed

36.

Nunnally J, Berstein I (1994) Psychometric methods, 3rd edn. McGraw-Hill, New York

37.

Edge SB (2010) American Joint Committee on Cancer. AJCC Cancer Staging Manual. Springer. http://www.springer.com/gp/book/9780387884424. Accessed 12 Apr 2017

38.

Pace A, Nisticò C, Cuppone F et al (2007) Peripheral neurotoxicity of weekly paclitaxel chemotherapy: a schedule or a dose issue? Clin Breast Cancer 7(7):550–554. doi:10.3816/CBC.2007.n.010 CrossRefPubMed

39.

Scripture CD, Figg WD, Sparreboom A (2006) Peripheral neuropathy induced by paclitaxel: recent insights and future perspectives. Curr Neuropharmacol 4(2):165–172 http://www.ncbi.nlm.nih.gov/pubmed/18615126. Accessed June 6, 2016CrossRefPubMedPubMedCentral

40.

Ventzel L, Jensen AB, Jensen AR, Jensen TS, Finnerup NB (2016) Chemotherapy-induced pain and neuropathy: a prospective study in patients treated with adjuvant oxaliplatin or docetaxel. Pain 157(3):560–568. doi:10.1097/j.pain.0000000000000404 CrossRefPubMed

41.

Eckhoff L, Knoop AS, Jensen M-B, Ejlertsen B, Ewertz M (2013) Risk of docetaxel-induced peripheral neuropathy among 1,725 Danish patients with early stage breast cancer. Breast Cancer Res Treat 142(1):109–118. doi:10.1007/s10549-013-2728-2 CrossRefPubMed

42.

Rouquette A, Falissard B (2011) Sample size requirements for the internal validation of psychiatric scales. Int J Methods Psychiatr Res 20(4):235–249. doi:10.1002/mpr.352 CrossRefPubMedPubMedCentral

43.

Knoerl R, Dudley W, Smith G, Bridges C, Kanzawa G, Smith EML Pilot testing a web-based system for the assessment and management of chemotherapy-induced peripheral neuropathy. Comput Informatics Nurs

Title: Electronic versus paper-pencil methods for assessing chemotherapy-induced peripheral neuropathy
Authors: Robert Knoerl
Evan Gray
Carrie Stricker
Sandra A. Mitchell
Kelsey Kippe
Gloria Smith
William N. Dudley
Ellen M. Lavoie Smith
Publication date: 01-11-2017
Publisher: Springer Berlin Heidelberg
Published in: Supportive Care in Cancer / Issue 11/2017
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-017-3764-y

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 11/2017

Effectiveness of a standardized patient education program on therapy-related side effects and unplanned therapy interruptions in oral cancer therapy: a cluster-randomized controlled trial

Prevention of palmoplantar erythrodysesthesia in patients treated with pegylated liposomal doxorubicin (Caelyx®)

Timing to antibiotic therapy in septic oncologic patients presenting without hypotension

‘We’re completely back to normal, but I’d say it’s a new normal’: a qualitative exploration of adaptive functioning in rural families following a parental cancer diagnosis

Optimal clinical assessment strategies for chemotherapy-induced peripheral neuropathy (CIPN): a systematic review and Delphi survey

The influence of unmet supportive care needs on anxiety and depression during cancer treatment and beyond: a longitudinal study of survivors of haematological cancers

Keynote webinar | Spotlight on antibody–drug conjugates in cancer